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Objectives: The study assessed dexmedetomidine utilization and practice variation over 
time in ventilated pediatric intensive care unit (PICU) patients; and evaluated differences 
in hospital outcomes between high- and low-dexmedetomidine utilization hospitals.
study design: This serial cross-sectional analysis used administrative data from PICU 
admissions in the pediatric health information system (37 US tertiary care pediatric hos-
pitals). Included admissions from 2007 to 2013 had simultaneous dexmedetomidine and 
invasive mechanical ventilation charges, <18 years of age, excluding neonates. Patient 
and hospital characteristics were compared as well as hospital-level severity-adjusted 
indexed length of stay (LOS), charges, and mortality.
results: The utilization of dexmedetomidine increased from 6.2 to 38.2 per 100 ven-
tilated PICU patients among pediatric hospitals. Utilization ranged from 3.8 to 62.8 per 
100 in 2013. Few differences in patient demographics and no differences in hospital-level 
volume/severity of illness measures between high- and low-utilization hospitals occurred. 
No differences in hospital-level, severity-adjusted indexed outcomes (LOS, charges, and 
mortality) were found.
conclusion: Wide practice variation in utilization of dexmedetomidine for ventilated PICU 
patients existed even as use has increased sixfold. Higher utilization was not associated 
with increased hospital charges or reduced hospital LOS. Further work should define the 
expected outcome benefits of dexmedetomidine and its appropriate use.
Keywords: physician’s practice patterns, intensive care units, pediatric, dexmedetomidine, diagnosis-related 
groups, drug utilization, respiration, artificial
Abbreviations: APR DRG, all-patient refined diagnosis related group; CHA, Children’s Hospital Association; CTC, 
clinical transaction classification; IQR, interquartile range; LOS, length of stay; PHIS, pediatric health information system; 
PICU, Pediatric Intensive Care Unit; RACHS-1, risk adjustment in congenital heart surgery, version 1; SOI, APR DRG severity 
of illness.
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inTrODUcTiOn
Dexmedetomidine is a centrally acting alpha-2 adrenergic recep-
tor agonist that was licensed by the Food and Drug Administration 
for use in adult patients in the intensive care unit and periopera-
tive areas in 1999. Initial adult and animal studies were conducted 
during the 1990s and early 2000s. Since that time the number of 
human reports indexed by Medline has dramatically increased. 
Pediatric reports began in 2002; and, since 2008, there have been 
approximately 50 published articles annually.
Numerous benefits of dexmedetomidine in pediatrics have 
been reported, but they are largely based on physiology evalu-
ated in animals and observational human studies. Randomized 
control trials are mostly limited to the peri-operative period. 
Dexmedetomidine’s reported benefits include (1) maintenance 
of spontaneous breathing in sedated patients, (2) potential neu-
roprotective qualities, (3) reduced need for/tolerance to other 
sedative agents, (4) sedative/heart rate control in cardiac surgical 
patients, (5) facilitating tracheal extubation, and (6) reduced 
delirium in the postoperative/prolonged sedation states (1–7).
As overall mortality is low in pediatric critical care, most 
research focuses on short-term, surrogate outcomes, such as 
length of stay (LOS) or duration of mechanical ventilation. 
Dexmedetomidine has demonstrated an ability to reduce opioid 
and benzodiazepine use as well as attenuating delirium in chil-
dren (8–10). These benefits have been hypothesized to shorten 
the critical illness course, but this has not been demonstrated 
consistently. Long-term studies regarding cognition and neuro-
development have not been performed on any sedative regimen. 
Dexmedetomidine, until coming off patent in 2014, has been 
approximately 12-fold more expensive than midazolam based 
on average wholesale pricing (11). Advocates argue that the cost 
differences are balanced by dexmedetomidine’s benefits, but this 
assertion has not been evaluated.
In 2012, the Institute of Medicine released its report The 
Best Care At Lower Cost (12) describing the model of a learn-
ing health care system. The report, in part, focuses on applying 
the  appropriate knowledgebase in real time to patient care and 
emphasizes the vast amount of unused clinical data available to 
researchers and clinicians. It also addressed the limitations of 
the traditional models of health care research that focus on the 
randomized control trial. Few randomized control trials exist 
for dexmedetomidine, and the numerous observational studies 
inconsistently suggest a variety of benefits. Without clear recom-
mendation for dexmedetomidine’s clinical use, physicians are left 
to apply their individual judgment.
This study hypothesizes that the utilization and variation have 
increased over time without clear evidence of benefit in outcomes 
related to healthcare utilization. It aims to define the time trends 
in utilization of dexmedetomidine in pediatric intensive care 
unit (PICU) patients who require invasive mechanical ventila-
tion by analyzing current, readily available administrative data. 
It  subsequently aims to use the naturally occurring practice 
variation between high- and low-dexmedetomidine utilization 
hospitals to evaluate the difference in aggregated hospital-level 
outcomes (hospital charges, LOS, and mortality) for all mechani-
cally ventilated PICU patients.
MaTerials anD MeThODs
study Design and Dataset
This was a retrospective, serial cross-sectional study of PICU 
admissions requiring invasive mechanical ventilation among 
hospitals reporting to the pediatric health information system 
(PHIS). PHIS is an administrative database that contains inpa-
tient, emergency department, and ambulatory surgery data from 
47 not-for-profit, tertiary care pediatric hospitals with teaching 
services in the United States. The hospitals are affiliated with the 
Children’s Hospital Association (CHA; Shawnee Mission, KS, 
USA), a business alliance of children’s hospitals. Data quality and 
reliability are assured through a joint effort between the CHA 
and participating hospitals. The data warehouse function for the 
PHIS database is managed by Thomson Reuters (Ann Arbor, MI, 
USA). Data are de-identified at the time of data submission, and 
data are subjected to a number of reliability and validity checks 
before being included in the database. The PHIS dataset contains 
revenue codes, which are mapped to the clinical transaction 
 classification (CTC) system. This permits more detailed evalua-
tion of billed services during a hospitalization (13). Ten hospitals 
that either did not submit revenue code information or had 
significant data quality issues were excluded from analysis. PHIS 
hospitals are commonly referred to as freestanding because they 
are required to be geographically distinct institutions. The formal 
definition of a freestanding children’s hospital also requires that it 
be self-governing and in a separate facility than an affiliated adult 
hospital. Because many large pediatric hospitals exist within the 
context of larger academic health systems, some PHIS hospitals 
are actually pediatric units within a general hospital.
The Institutional Review Board of Indiana University approved 
this study and waived the requirement of informed consent.
identification of sample
This analysis was limited to inpatients admitted between January 
1, 2007 and December 31, 2013 from 37 PHIS hospitals. As hos-
pital discharge after critical illness can be delayed, data analysis 
and results were reported in terms of hospital admission date in 
order to group care that occurred in similar time periods. Since 
administrative data are captured at the time of discharge, 2013 
admissions were included if discharge occurred by December 31, 
2014 (the most recent PHIS data load). Admissions were included 
if the patient was <18 years of age and had the PHIS ICU flags 
(Data Sheet S1 in Supplementary Material). Dexmedetomidine 
use in patients who were not invasively ventilated (non-invasive 
positive pressure ventilation or no respiratory support) was 
excluded from this analysis. Neonatal admissions with Neonatal 
ICU flag or All-Patient Refined Diagnosis Related Group (3M 
Health Information Systems, APR DRG) version 30 codes related 
to neonatal care were excluded (Data Sheet S1 in Supplementary 
Material).
analysis of hospital-level Utilization and 
Outcomes
Utilization of dexmedetomidine was defined as the presence of a 
CTC pharmacy code for dexmedetomidine (114055) occurring 
on the same day of service as a CTC service code for mechanical 
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ventilation (521166, 521169). Only admissions with an intensive 
care unit service charge were included. CTC codes reflect care 
that was ordered; administration and dosing cannot be verified. 
Utilization of dexmedetomidine over time was expressed as the 
rate of admissions with dexmedetomidine CTC code per 100 
invasively ventilated PICU admissions. Utilization was evaluated 
in 6-month time intervals based on hospital admission date.
Characteristics of mechanically ventilated PICU patients 
were aggregated at the hospital-level to allow comparisons 
among hospitals with different levels of dexmedetomidine 
utilization. These characteristics include age groups (<1, 
1–4, 5–13, and ≥13  years), gender, race/ethnicity (Caucasian, 
African-American, and Hispanic), and primary payer (public 
and private). Dexmedetomidine use in patients with complex 
chronic conditions was compared (14). Since dexmedetomi-
dine has potential benefits in (1) cardiac surgical patients, (2) 
 neurosurgical/neurological care (including neuro-trauma), and 
(3) respiratory disease with prolonged invasive ventilation, these 
groups were analyzed separately based on APR DRG codes (Data 
Sheet S1 in Supplementary Material).
Hospital characteristics were aggregated to facilitate com-
parisons. Dexmedetomidine utilization, as measured in 2012 and 
2013, was grouped into tertiles representing high, intermediate, 
and low utilization. The effects of PICU volume and severity of 
illness (SOI) on dexmedetomidine utilization was assessed. The 
PICU flag defined the total number of annual PICU admissions; 
and the cardiac surgical volume, defined as the sum of the risk 
adjustment in congenital heart surgery, version 1 (RACHS-1), 
categories 1–6 for all patients admits to the hospital (15). To 
evaluate SOI the proportion of PICU patients who required inva-
sive mechanical ventilation and the proportion of PICU patients 
in each APR DRG SOI category 3 and 4 were determined for each 
hospital. SOI categories 3 and 4 are the most severely ill patients.
Hospital-level outcomes for pediatric patients requiring the 
PICU admission and mechanical ventilation were severity-
adjusted LOS, charge, and mortality indexes. These indexes were 
calculated based on the total observed LOS (or charges/mortality) 
for the population of invasively ventilated PICU patients divided 
by the total severity-adjusted expected LOS (or charges/mortality) 
at each hospital. NICU admissions were not excluded for cardiac 
surgical patients, as many have encounters in both units. The 
severity adjustment was determined from the APR DRG weight-
ing structure defined by 3M and Truven (16). Each APR DRG has 
four corresponding SOI levels that are coded based on diagnoses, 
procedures, and demographics. There are specified weights for 
LOS, charges, and mortality for each APR DRG and severity level. 
Adjusted hospital charges were used for the observed charges, 
which accounts for differences in value of medical services in 
different economic markets. Severity-adjusted LOS, charge, and 
mortality indexes were also determined for each diagnostic group 
to look for differences in specific subpopulations. The use of APR 
DRG severity adjustment in pediatric and intensive care literature 
has been discussed (17–20).
statistical analysis
All analyses were completed with Stata 12.1 (Stata Corp., College 
Station, TX, USA).
The change in utilization of dexmedetomidine from January 
2007 through December 2013 was evaluated by comparing the 
median rate of utilization, interquartile range (IQR), and full range 
for each 6-month time period for available hospitals. The trend 
in utilization over time was evaluated using variance-weighted 
least squares regression (21). Because of an obvious change in 
the growth of utilization occurring in 2011 or 2012, a two-part 
regression model was used. Only 3 hospitals (of the 37) did not 
have complete utilization data going back to 2007, but they all 
contributed at least 5 years of data.
To compare outcomes by dexmedetomidine utilization, 
 dexmedetomidine utilization was characterized in the 2012 
and 2013 admissions. Hospitals were grouped by their utili-
zation patterns as previously discussed. In each hospital, the 
proportions of each patient characteristic for those receiv-
ing dexmedetomidine were determined. To evaluate for a 
potential effect of dexmedetomidine the median proportion 
and IQR across the hospitals in the low- and high-utilization 
groups were then compared using ranksum testing. Aggregate 
hospital characteristics were similarly evaluated. Severity-
adjusted indexed outcomes were compared using ranksum and 
presented as median with IQR. The intermediate utilization 
group was presented for comparison purposes only. Statistical 
significance was set at a p < 0.05.
resUlTs
Trends in Variation and Utilization in 
Dexmedetomidine, 2007–2013
Median utilization of dexmedetomidine across the 37 pediatric 
hospitals increased from 6.2 to 38.3 per 100 mechanically 
ventilated PICU admissions (an over sixfold increase in 7 years, 
Figure 1). There was a statistically significant increase in utiliza-
tion from 2007 through 2012; the utilization was constant in 2012 
and 2013. Despite the expected increase in utilization, practice 
variation persisted. The size of the IQR did not decrease; and 
furthermore, in 2013, the full range of utilization was 3.8 to 62.8 
per 100 mechanically ventilated PICU patients.
Patient characteristics in high- and  
low-Utilization hospitals, 2012–2013
While the median rate of dexmedetomidine utilization was 
statistically different in low- vs. high-utilization hospitals (23.7 
vs. 50.6 per 100 mechanically ventilated PICU admissions), 
there were only nominal differences in distribution of patient 
age, gender, race/ethnicity, and primary payers for those who 
received dexmedetomidine (Table  1). There was a statistically 
significant lower median proportion of toddlers 1–4  years in 
high-utilization hospitals, with a likely increased proportion of 
children <1 year of age. Regardless of the level of dexmedetomi-
dine utilization in a particular hospital, approximately 50–55% 
of mechanically ventilated patients who received dexmedeto-
midine were admitted for conditions that have been reported 
to benefit from dexmedetomidine (e.g., cardiovascular surgery, 
neurosurgery/neurological care, and prolonged mechanical 
ventilation). There were no differences in pattern of utilization 
TaBle 1 | Patient characteristics among intermediate, high, and low utilization hospitals, 2012–2013.
low utilization intermediate utilization high utilization
Median % iQr Median % iQr Median % iQr
Group’s median utilization rate 23.7 39.7 50.6
Female gender 43.3 (39.7, 45.0) 43.5 (41.2, 45.2) 42.9 (41.7, 45.3)NS
Age groups
 0–1 year 35.6 (29.4, 42.7) 39.3 (32.8, 43.0) 41.0 (38.8, 43.1)NS
 1–4 years 33.4 (30.3, 36.3) 29.0 (28.1, 32.4) 28.8 (26.7, 29.8)1
 5–13 years 16.4 (14.6, 20.0) 19.0 (17.4, 23.0) 18.8 (17.6, 20.1)NS
 ≥13 years 12.3 (9.7, 13.6) 10.9 (9.5, 13.1) 12.0 (10.7, 13.5)NS
Race categories
 Caucasian 48.2 (37.0, 57.2) 49.8 (39.0, 70.9) 54.4 (46.3, 62.9)NS
 African-American 17.9 (3.4, 23.9) 16.2 (9.1, 28.2) 15.1 (7.0, 20.0)NS
 Hispanic 11.9 (7.7, 23.4) 9.2 (4.6, 25.8) 11.9 (2.0, 32.3)NS
Payer categories
 Private payer 36.2 (28.1, 44.7) 38.5 (33.0, 43.9) 34.1 (31.1, 42.1)NS
 Public payer 62.0 (51.9, 68.8) 56.3 (53.9, 63.7) 62.0 (55.5, 64.6)NS
Disease states
 Complex chronic illness 83.3 (77.1, 84.7) 86.0 (78.9, 88.2) 82.4 (79.8, 86.1)NS
 Cardiovascular surgery 29.9 (19.7, 41.7) 34.7 (25.1, 41.6) 30.4 (27.9, 41.3)NS
 Neurosurgical/neurological care 7.4 (6.2, 10.3) 7.7 (5.0, 10.3) 6.7 (4.9, 11.4)NS
 Prolonged mechanical ventilation 18.3 (10.9, 20.7) 13.3 (11.6, 15.8) 13.5 (11.6, 16.0)NS
Median percent of patients in each characteristic among mechanically ventilated PICU patients simultaneously billed for mechanical ventilation and dexmedetomidine.
Statistical difference between high- and low-utilization groups: NS, not significant (p > 0.05), 1p < 0.01.
FigUre 1 | Dexmedetomidine utilization in ventilated pediatric intensive care patients, 2007–2013. Rate of utilization per 100 invasively ventilated 
PICU patients in 6-month time intervals. Markers reflect the median rate of utilization with the IQR as the gray box. Full range denoted by the wiskers. Median 
rate of increase overtime is denoted by the solid line and indicates a rate of increase of 7 PICU patients per 100 each year until 2012 (p = 0.02) after which it 
remains constant.
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in these disease states based on the level of dexmedetomidine 
utilization at the hospital.
characteristics of hospitals in high and 
low-Utilizing PicUs, 2012–2013
In general, hospitals in the high- and low-utilization groups were 
not different. They had similar numbers of overall PICU admis-
sions, cardiac surgical volume, and SOI measures (proportions 
of patients requiring mechanical ventilation and APR DRG SOI 
categories 3 and 4) (Table 2).
hospital Outcomes for high and low 
Utilizers of Dexmedetomidine, 2012–2013
Severity-adjusted LOS, charges, and mortality as defined by the 
observed vs. expected ratio for all mechanically ventilated PICU 
patients were not different in low and high-utilizing hospitals. The 
TaBle 2 | hospital characteristics among intermediate, high, and low utilization hospitals.
low utilization intermediate utilization high utilization
Median iQr Median iQr Median iQr
Volume measures (n)
 Annual PICU admissions 1582 (977, 2602) 2283 (1678, 2657) 1614 (1475, 2241)NS
 Annual cardiac surgical volume 184 (116, 340) 233 (145, 314) 224 (180, 249)NS
PICU severity of illness measures (%)
 Mechanical ventilation admits 36.8% (26.9, 53.4) 43.9% (37.5, 46.9) 36.9% (31.3, 45.2)NS
 APR DRG SOI category 3 32.4% (28.7, 34.3) 31.7% (29.0, 33.7) 30.5% (29.7, 34.0)NS
 APR DRG SOI category 4 20.3% (15.2, 22.2) 24.2% (17.4, 27.2) 20.7% (19.1, 21.9)NS
Statistical difference between high- and low-utilization groups: NS, not significant (p > 0.05).
TaBle 3 | indexed hospital-level outcomes among intermediate, high, and low utilization hospitals.
low utilization intermediate utilization high utilization
Median iQr Median iQr Median iQr
Severity-adjusted observed vs. expected LOS
 Overall 1.29 (1.11, 1.52) 1.19 (1.07, 1.42) 1.28 (1.18, 1.46)NS
 Cardiovascular surgery 1.18 (1.07, 1.51) 1.13 (1.10, 1.29) 1.11 (1.01, 1.24)NS
 Neurosurgical/neurological care 1.19 (1.00, 1.32) 1.01 (0.93, 1.59) 1.37 (1.16, 1.60)NS
 Prolonged mechanical ventilation 1.17 (1.07, 1.45) 1.12 (0.96, 1.43) 1.27 (1.13, 1.42)NS
Severity-adjusted observed vs. expected charges
 Overall 1.73 (1.15, 2.30) 1.85 (1.40, 2.00) 1.61 (1.46, 1.97)NS
 Cardiovascular surgery 1.45 (1.25, 2.39) 1.68 (1.29, 1.85) 1.64 (1.44, 1.72)NS
 Neurosurgical/neurological care 1.62 (1.12, 1.80) 1.65 (1.46, 1.98) 1.62 (1.51, 1.97)NS
 Prolonged mechanical ventilation 1.54 (0.89, 2.32) 1.73 (1.20, 2.13) 1.44 (1.36, 1.74)NS
Severity-adjusted observed vs. expected mortality
 Overall 0.83 (0.70, 1.04) 0.81 (0.71, 0.95) 0.83 (0.71, 0.88)NS
 Cardiovascular surgery 0.82 (0.59, 0.90) 0.68 (0.47, 0.92) 0.84 (0.64, 0.89)NS
 Neurosurgical/neurological care 0.81 (0.72, 1.06) 0.86 (0.58, 0.96) 0.77 (0.55, 0.91)NS
 Prolonged mechanical ventilation 0.93 (0.65, 1.05) 0.85 (0.70, 0.96) 0.85 (0.75, 1.00)NS
Statistical difference between high- and low-utilization groups: NS, not significant (p > 0.05).
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lack of difference persisted even when evaluating the subgroups 
of disease categories (cardiovascular surgery, neurosurgical/ 
neurological care, or prolonged mechanical ventilation) (Table 3).
DiscUssiOn
This analysis presented the natural history of the rise in utiliza-
tion of dexmedetomidine in invasively ventilated PICU patients 
in large pediatric hospitals following its introduction and 
published use. The increase in utilization was not surprising 
given that practitioners will naturally increase their usage of 
a potentially beneficial medication, especially when published 
literature may support the practice. This analysis also demon-
strated that as utilization increases practice variation persists. 
While one might have expected that all hospitals would have 
increased their use similarly, this analysis indicated that some 
hospitals continue to have very little use of dexmedetomidine 
despite the growing trend.
This type of practice variation is ubiquitous in medical care even 
when there is evidence for effective care (22), including pediatric 
critical care (23, 24). Because most critical care therapies are not 
rigorously evaluated, their use is a product of supply sensitive and 
physician preference-sensitive care. Supply sensitive care should 
be driven by the optimal rate of utilization; as excess utilization 
has been found to be harmful (25, 26). Preference-sensitive care 
is traditionally balanced by the patient’s preferences in regards 
to therapies and outcomes, which is not possible in most critical 
care decisions, so physicians invoke their own practice styles (22, 
27). The differences in practice style can increase costs without 
improving outcomes for patients (27).
Differences in patient demographics between high- and low-
utilization hospitals did not account for differences in utilization. 
PICU volume and SOI did not account for differences in utiliza-
tion, either. It appeared that about half of the use of dexmedeto-
midine in ventilated PICU patients occurred in disease states 
with suggested benefit. Current research may support its use in 
these populations, but the extrapolation to other populations may 
contribute to practice variation.
Dexmedetomidine has been touted to improve outcomes by 
reducing the negative effects of opioids and benzodiazepines, 
facilitating tracheal extubation, and potentially shortening the 
duration of mechanical ventilation (2–9). A reduction in mechani-
cal ventilation duration may shorten hospital LOS. If a reduction 
in PICU therapies, such as mechanical ventilation, or overall 
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hospital LOS can translate into reduced healthcare expenditures 
that offset the cost of dexmedetomidine then there is a substantial 
benefit. Because many factors contribute to LOS, this study was 
not designed to compare individual patients who received dexme-
detomidine. Instead, this study assessed whether hospitals that had 
high use of dexmedetomidine had shorter observed vs. expected 
LOS (indexed LOS) than low-utilization hospitals. This method-
ology potentially biases the analysis toward finding a reduction. 
Because high-utilization hospitals use dexmedetomidine in more 
patients, increased utilization should have a greater effect on the 
indexed LOS. No reduction in severity-adjusted indexed LOS 
was found. Because of the added expense of dexmedetomidine, a 
greater indexed charge ratio in higher utilization hospitals might 
have been expected, but this difference was not found. No mortal-
ity benefit has been suggested with dexmedetomidine in previous 
studies, nor was one found in this study even with the relatively 
large sample size. While this severity-adjustment methodology is 
imperfect it likely accounts for many differences in hospitalized 
patients and the care provided. Furthermore, there were no dif-
ferences in other SOI measures across hospitals.
This study presents an analysis using administrative data to 
evaluate practice variation in pediatric critical care around the 
use of dexmedetomidine and is subject to the standard limitations 
of administrative data (28). This analysis relies on revenue data 
specifically the CTC system, which reflects care that was billed not 
necessarily administered. This analysis focused on evaluating the 
hospital-level rather than the patient-level care patterns. While 
this may limit its ability to be applied to a particular patient, this 
study was intended to assess the effect of a general practice style 
on overall outcomes. There are also limitations with the APR 
DRG severity-adjustment process including many factors that 
influence LOS and hospital charges. There are physiologically 
based severity-adjustment models available, but none can be 
applied administratively across multiple hospitals.
Despite these limitations, PHIS is the only pediatric specific, 
multi-institutional dataset where investigators can begin to assess 
general practice patterns and the potential affects on outcomes. 
This study reflects current practice patterns. While limited to 
patients admitted in 2013, it included many patients discharged in 
2014. This type of analysis adopts the framework specified by the 
Institute of Medicine for a Learning Health Care System. The wide 
practice variation around the use of dexmedetomidine in the PICU 
exists without clear benefits to outcomes as far as LOS, charges, and 
mortality warrants further study. Clinically, dexmedetomidine 
seems to be a useful sedative in the PICU, but unsupported physi-
cian preference should not drive utilization. This study suggests 
that further work should not be focused on outcomes like LOS 
and mortality but rather on more patient-centered outcomes, such 
as delirium or long-term neurodevelopment. While this study did 
not find increased charges associated with dexmedetomidine use, 
benefits in long-term outcomes may have cost benefits for the 
entire healthcare system. As dexmedetomidine comes off patent 
and its cost lowers (presumably utilization will increase), it will 
be critical to understand how to use this medication, the optimal 
patient selection, and the expected benefits.
cOnclUsiOn
Dexmedetomidine utilization has increased sfold in PICU 
patients who are mechanically ventilated, but continues to have 
15-fold variation in practice with some hospitals using it rarely 
and others using it in over 60% of patients. There does not appear 
to be a significant difference in overall severity-adjusted LOS or 
hospital charges between hospitals that use dexmedetomidine 
frequently as compared to those that do not. Further work should 
explore the other potential outcome benefits (such as delirium 
or neurodevelopmental affects) of using dexmedetomidine in 
invasively ventilated patients.
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